Interpace Biosciences, Inc. filed its 10-K on Mar 27, 2023 for the period ending Dec 31, 2022. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.37 USD | -5.23% | -5.52% | +26.85% |
May. 09 | Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
1st Jan change | Capi. | |
---|---|---|
+26.85% | 6M | |
+2.25% | 6.61B | |
+3.53% | 1.29B |
- Stock Market
- Equities
- IDXG Stock
- News Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. Auditor Raises 'Going Concern' Doubt